Phase Libtayo clinical trials developed by Regenerative Element and Sanofi show good results

Regeneroncompany(http://recently announced that its PD-1 inhibitor Libalo,developed with Sanofi, as a single-drug therapy, has shown significantly better results in the first-stage treatment of patients with advanced non-small cell lung cancer (NSCLC) in theof the 3st stage of clinicaltrial(http:// chemotherapyCurrently, Libtayo is treating patients with advanced NSCLC in two Phase 3 clinical trials as a single drug, or in combination with chemotherapyLibtayo is an all-humanized anti-PD-1 monoclonal antibody developed by Sanofi and RegenerationIt helps the body's immune system kill tumor cells by blocking the PD-1 signaling pathwayPreviously, Libtayo has been approved in the United States, the European Union, Canada and Brazil for the treatment of metastatic skin squamous cell carcinoma (CSCC) or for localized advanced CSCC patients who cannot receive curative surgery or radiotherapyLibtayo is also treating patients with cervical cancer, head and neck squamous cell carcinoma, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin's lymphoma and non-Hodgkin's lymphoma in clinical trialsIn Phase 3 clinical trials of Patients with NSCLC treated with PD-L1 expression levels of 50% in Libtayo as a single-drug therapy, the participants had IIIB, IIIC or PHASE IV scaly or non-scaly NSCLC, were not suitable for chemotherapy and radiation therapy, and had not received systemic therapy for advanced diseasesThe mid-termanalysis of the(http:// showed that 42 percent of PATIENTS TREATED WITH LIBTAYO HAD ORR compared to individual chemotherapy, much like Keytruda, which was becoming the standard care therapy for some lung cancer patients, in previous phase 3 trials, and 22 percent in the chemotherapy group